Invasive Fungal Infections

Infectious Disease·MeSH: Invasive Fungal Infections

6 drugs in development·4 companies·2 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Noxafil	Merck & Co., Inc. (MRK)

Phase 3(1)

Drug	Company
rezzayo	CorMedix Inc. (CRMD)

Unknown(4)

Drug	Company
amphotericin b liposome for injection (strength	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
amphotericin b liposome for injection (strength	NYMOX PHARMACEUTICAL CORP (NYMXF)
amphotericin b liposome for injection (trade name	NYMOX PHARMACEUTICAL CORP (NYMXF)
amphotericin b liposome for injection (trade name	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

BioSniper tracks 6 drugs in development for Invasive Fungal Infections across 4 companies.

There are 2 clinical trials targeting Invasive Fungal Infections tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.